PHIO | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 6%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

13.73%

1 Month

28.89%

3 Months

2.65%

6 Months

-45.28%

1 Year

-10.77%

2 Year

31.52%

Key data

Stock price

$1.16

P/E Ratio

N/A

DAY RANGE

$1.15 - $1.23

EPS

-$1.70

52 WEEK RANGE

$0.81 - $4.19

52 WEEK CHANGE

-$10.08

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

11.617 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

3.85

PUBLIC FLOAT

AVERAGE 10 VOLUME

$534,207

AVERAGE 30 VOLUME

$10,485,759

Company detail

CEO: Geert C. PhD
Region: US
Website: phiopharma.com
Employees: 10
IPO year: 2010

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT) PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression.

PHIO - Phio Pharmaceuticals Corp.